Ico Therapeutics (ICOTF) 0.0400 $ICOTF iCo Ther
Post# of 273242
Posted On: 09/21/2016 7:03:59 AM
Ico Therapeutics (ICOTF) 0.0400 $ICOTF
iCo Therapeutics Announces First Quarter 2016 Financial Results
CNW Group - Wed May 25, 3:00PM CDT
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2016. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS".
ICO.VN: 0.055 (unch)
iCo Therapeutics Announces Year End 2015 Financial Results
CNW Group - Thu Apr 14, 3:00PM CDT
iCo Therapeutics ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the year ended December 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS".
ICO.VN: 0.055 (unch)
iCo Strategic Reorganization
CNW Group - Mon Jan 18, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today announced that effective immediately, in an effort to preserve its asset base and maximize shareholder value, the company is undertaking a strategic re-organization.
ICO.VN: 0.055 (unch)
iCo Therapeutics Announces Changes to Board of Directors
CNW Group - Thu Dec 24, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today announced the appointment of Susan Koppy and John Meekison to iCo's Board of Directors.
ICO.VN: 0.055 (unch), NVS: 81.06 (+1.12)
/C O R R E C T I O N from Source -- iCo Therapeutics Inc./
PR Newswire - Tue Nov 24, 6:21PM CST
In the news release, iCo Therapeutics Announces Third Quarter 2015 Financial Results, issued today by iCo Therapeutics Inc. over CNW, we are advised by the company that in the paragraph Summary Third Quarter 2015 Results, the last sentence should have read "Immune Pharmaceuticals Inc.", rather than "Immune Therapeutics Inc." as originally issued inadvertently. The complete, corrected release follows:
ICO.VN: 0.055 (unch), IMNP: 0.29 (-0.02)
iCo Therapeutics Announces Third Quarter 2015 Financial Results
CNW Group - Tue Nov 24, 4:00PM CST
iCo Therapeutics ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended September 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS".
ICO.VN: 0.055 (unch)
iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program
CNW Group - Mon Oct 26, 7:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF) today announced that the company has engaged Corealis Pharma Inc. ("Corealis" a contract manufacturing organization, for analytical development, formulation optimization and scale-up of the amphotericin B oral delivery system. The preparation and regulatory filings for this program are expected to be completed in 2016, with Phase 1A study data available in 2017.
ICO.VN: 0.055 (unch)
iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders
PR Newswire - Fri Jun 26, 3:00PM CDT
iCo Therapeutics ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today announced that all nominees listed in the management information circular dated June 1, 2015 were elected as directors at its 2015 Annual Meeting of Shareholders, held earlier today, June 26 2015. On a vote by ballot, the following 5 nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows:
ICO.VN: 0.055 (unch)
Immune Pharmaceuticals Inc. (Nasdaq: IMNP) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri May 22, 9:00AM CDT
What:
IMNP: 0.29 (-0.02), NDAQ: 69.62 (-0.18)
Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee
PR Newswire - Tue Apr 21, 7:30AM CDT
Immune Pharmaceuticals Inc., or "Immune" (NASDAQ: IMNP) announced that its Board of Directors has elected Rene-Pierre Azria as a Director and the Chair of the Transaction and Pricing Committee, with oversight on strategic and financial transactions. Mr. Azria will also be a member of the Audit Committee, the Compensation Committee and the Corporate Governance and Nomination Committee.
ICO.VN: 0.055 (unch), IMNP: 0.29 (-0.02)
Immune Pharmaceuticals to Develop Novel Topical Nanoparticle Formulation of AmiKet
PR Newswire - Mon Mar 16, 3:15PM CDT
Immune Pharmaceuticals Inc. ("Immune", the "Company" (NASDAQ: IMNP) announced today that it has entered into a binding memorandum of understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents in order to facilitate the development of a topical nanoparticle formulation of Immune's neuropathic pain drug, AmiKet(TM).
ICO.VN: 0.055 (unch), IMNP: 0.29 (-0.02)
CEO Dr. Daniel Teper of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014
Marketwired - Tue Dec 09, 10:13AM CST
Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), a company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer, announced today that CEO Daniel Teper will be interviewed live tomorrow by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's The Traders Network Show. In this exclusive 2-segment interview, Mr. Teper will discuss the company's lead product candidate, Bertilimumab, which is in clinical development for moderate to severe ulcerative colitis and crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
IMNP: 0.29 (-0.02)
iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update
PR Newswire - Fri Nov 28, 4:00PM CST
iCo Therapeutics ("iCo" or "the Company" (TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS".
ICO.VN: 0.055 (unch)
iCo Therapeutics Announces First Quarter 2016 Financial Results
CNW Group - Wed May 25, 3:00PM CDT
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended March 31, 2016. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS". ICO.VN: 0.055 (unch)
iCo Therapeutics Announces Year End 2015 Financial Results
CNW Group - Thu Apr 14, 3:00PM CDT
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the year ended December 31, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS". ICO.VN: 0.055 (unch)
iCo Strategic Reorganization
CNW Group - Mon Jan 18, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today announced that effective immediately, in an effort to preserve its asset base and maximize shareholder value, the company is undertaking a strategic re-organization. ICO.VN: 0.055 (unch)
iCo Therapeutics Announces Changes to Board of Directors
CNW Group - Thu Dec 24, 6:00AM CST
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today announced the appointment of Susan Koppy and John Meekison to iCo's Board of Directors. ICO.VN: 0.055 (unch), NVS: 81.06 (+1.12)
/C O R R E C T I O N from Source -- iCo Therapeutics Inc./
PR Newswire - Tue Nov 24, 6:21PM CST
In the news release, iCo Therapeutics Announces Third Quarter 2015 Financial Results, issued today by iCo Therapeutics Inc. over CNW, we are advised by the company that in the paragraph Summary Third Quarter 2015 Results, the last sentence should have read "Immune Pharmaceuticals Inc.", rather than "Immune Therapeutics Inc." as originally issued inadvertently. The complete, corrected release follows:
ICO.VN: 0.055 (unch), IMNP: 0.29 (-0.02)
iCo Therapeutics Announces Third Quarter 2015 Financial Results
CNW Group - Tue Nov 24, 4:00PM CST
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the quarter ended September 30, 2015. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS". ICO.VN: 0.055 (unch)
iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program
CNW Group - Mon Oct 26, 7:00AM CDT
iCo Therapeutics Inc. ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF) today announced that the company has engaged Corealis Pharma Inc. ("Corealis" a contract manufacturing organization, for analytical development, formulation optimization and scale-up of the amphotericin B oral delivery system. The preparation and regulatory filings for this program are expected to be completed in 2016, with Phase 1A study data available in 2017. ICO.VN: 0.055 (unch)
iCo Therapeutics Announces Voting & Election Results from Annual Meeting of Shareholders
PR Newswire - Fri Jun 26, 3:00PM CDT
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today announced that all nominees listed in the management information circular dated June 1, 2015 were elected as directors at its 2015 Annual Meeting of Shareholders, held earlier today, June 26 2015. On a vote by ballot, the following 5 nominees proposed by management were elected as Directors of iCo Therapeutics to serve until the Company's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favour of individual nominees as follows: ICO.VN: 0.055 (unch)
Immune Pharmaceuticals Inc. (Nasdaq: IMNP) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Fri May 22, 9:00AM CDT
What:
IMNP: 0.29 (-0.02), NDAQ: 69.62 (-0.18)
Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee
PR Newswire - Tue Apr 21, 7:30AM CDT
Immune Pharmaceuticals Inc., or "Immune" (NASDAQ: IMNP) announced that its Board of Directors has elected Rene-Pierre Azria as a Director and the Chair of the Transaction and Pricing Committee, with oversight on strategic and financial transactions. Mr. Azria will also be a member of the Audit Committee, the Compensation Committee and the Corporate Governance and Nomination Committee.
ICO.VN: 0.055 (unch), IMNP: 0.29 (-0.02)
Immune Pharmaceuticals to Develop Novel Topical Nanoparticle Formulation of AmiKet
PR Newswire - Mon Mar 16, 3:15PM CDT
Immune Pharmaceuticals Inc. ("Immune", the "Company"
(NASDAQ: IMNP) announced today that it has entered into a binding memorandum of understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents in order to facilitate the development of a topical nanoparticle formulation of Immune's neuropathic pain drug, AmiKet(TM). ICO.VN: 0.055 (unch), IMNP: 0.29 (-0.02)
CEO Dr. Daniel Teper of Immune Pharmaceuticals, Inc. (NASDAQ: IMNP) to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014
Marketwired - Tue Dec 09, 10:13AM CST
Immune Pharmaceuticals, Inc. (NASDAQ: IMNP), a company that applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer, announced today that CEO Daniel Teper will be interviewed live tomorrow by host Michael Yorba on Clear Channel - iHeart Business Talk Radio's The Traders Network Show. In this exclusive 2-segment interview, Mr. Teper will discuss the company's lead product candidate, Bertilimumab, which is in clinical development for moderate to severe ulcerative colitis and crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. We encourage investors, analysts, industry professionals and all interested parties to tune in and listen live via Clear Channel's nationally syndicated iHeart Radio stream.
IMNP: 0.29 (-0.02)
iCo Therapeutics Announces Third Quarter 2014 Financial Results and Corporate Update
PR Newswire - Fri Nov 28, 4:00PM CST
iCo Therapeutics ("iCo" or "the Company"
(TSX-V: ICO) (OTCQX: ICOTF), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS". ICO.VN: 0.055 (unch)
(0)
(0)Scroll down for more posts ▼